emergency use authorization

The FDA also reissued Emergency Use Authorizations for SARS-CoV-2 tests from Roche and Express Gene to reflect their permitted use with additional sample types.

The ELISA-based test has shown 98.8 percent sensitivity and 99.6 percent specificity for detecting SARS-CoV-2 specific IgG against two virus antigens.

The loop-mediated isothermal amplification test runs on a battery-powered device to provide self-testing individuals with results in approximately 30 minutes.

The assay is the first SARS-CoV-2 neutralizing antibody test to receive Emergency Use Authorization from the FDA.

Fluidigm tallied $39.9 million in revenues compared to $26.5 million a year ago, and well above analysts' consensus estimate of $32.5 million.

The RT-PCR-based test was first authorized in March for the detection of SARS-CoV-2 nucleic acid in specimens collected by a healthcare provider.

The firm's molecular solutions revenues increased 79 percent to $31.7 million due to COVID-19 testing demand.

The test was first authorized in May for the detection of the SARS-CoV-2 N, E, and ORF1a genes in nasopharyngeal swabs and other specimens.